To address this challenge, a highly sensitive and targeted T1‐T2 dual‐mode magnetic resonance imaging (MRI) nanoprobe is designed and developed, specifically targeting early‐stage liver fibrosis characterized by the activation of hepatic stellate cells (HSCs) and the overexpression of platelet‐derived growth factor receptor β (PDGFRβ). The gene discussed is PDGFRB; the disease is Hepatic fibrosis.